Table 3. Metrics of Response to Chemotherapy Among 280 Matched Patients.
| Characteristic | No. (%) of patients | P value | ||
|---|---|---|---|---|
| All (n = 280) | First-line chemotherapy regimen | |||
| FOLFIRINOX (n = 140) | GA (n = 140) | |||
| Radiographic measures after treatment | ||||
| Reduction in primary tumor volume | ||||
| Yes | 197 (70) | 100 (71) | 97 (69) | .70 |
| No | 83 (30) | 40 (29) | 43 (31) | |
| %Δvol, Median (range) | 20 (−240 to 90) | 30 (−240 to 90) | 10 (−150 to 90) | .10 |
| RECIST 1.1 | ||||
| CR | 0 | 0 | 0 | .001 |
| PR | 35 (13) | 27 (19) | 8 (6) | |
| SD | 219 (78) | 102 (73) | 117 (83) | |
| PD | 26 (9) | 11 (8) | 15 (11) | |
| Local tumor downstaginga | ||||
| Yesb | 13 (8) | 7 (8) | 6 (7) | .70 |
| Nob | 154 (92) | 79 (92) | 75 (93) | |
| Serologic measures after treatment | ||||
| Posttreatment CA 19-9 level, median (range), U/mL | 59 (1 to 11 570) | 59 (1 to 5813) | 63 (1 to 11 570) | .70 |
| Change in CA 19-9 | ||||
| Not expressed | 14 (5) | 7 (5) | 7 (5) | .90 |
| Normal to normal | 41 (15) | 22 (16) | 19 (14) | |
| Elevated to normal | 59 (21) | 31 (22) | 28 (20) | |
| Elevated to elevated | 161 (58) | 78 (56) | 83 (59) | |
| Normal to elevated | 5 (2) | 2 (1) | 3 (2) | |
Abbreviations: CA 19-9, cancer antigen 19-9; CR, complete response; FOLFIRINOX, fluorouracil, leucovorin, irinotecan, and oxaliplatin; GA, gemcitabine plus nanoparticle albumin-bound paclitaxel; PD, progressive disease; PR, partial response; RECIST 1.1, Response Evaluation Criteria in Solid Tumors, version 1.1; SD, stable disease; %Δvol, percentage of volume change in primary tumor.
SI conversion factor: To convert CA 19-9 levels to kU/L, multiply by 1.
a
Downstaging was defined as any change from locally advanced disease to either borderline resectable or resectable disease or from borderline resectable to resectable disease.
b
Percentage of patients with borderline resectable or locally advanced disease at baseline (n = 167).